ScripVyne Therapeutics is looking for a partner to develop repibresib after the drug failed in a Phase IIb clinical trial among patients with vitiligo, as the company still sees potential for its lead prod
ScripBristol Myers Squibb is hopeful that it still has a chance to expand the label for Reblozyl (luspatercept-aamt) after a Phase III trial failed to meet the primary endpoint but met several secondary en
ScripSun Pharma’s Leqselvi (deuruxolitinib) has finally hit the US market, pitting the JAK1/JAK2 inhibitor against its big pharma rivals, after the Indian group settled a patent dispute with Incyte. Leqsel
ScripArtificial intelligence-enabled drug discovery and development is one of the hottest topics in the biopharmaceutical industry, capturing the imaginations of investors, entrepreneurs and veterans alike